graphic
News > Companies
Prozac licensing deal OK'd
April 13, 2000: 11:20 a.m. ET

Eli Lilly gets go-ahead to market new version of antidepression drug
graphic
graphic graphic
graphic
NEW YORK (CNNfn) - Eli Lilly and Co. said Thursday federal regulators have approved its pact to license a new version of the widely-prescribed antidepressant Prozac now under development.
    Lilly shares gained about 6 percent on the news and after an analyst upgrade, while stock in its proposed licensing partner, Sepracor Inc. (SEPR: Research, Estimates), surged 24 percent.
    If the new drug is approved, it could delay generic competition to Prozac for years. The patent on the existing Prozac expires in 2003. The lucrative drug had sales of about $2.6 billion last year.
    graphic
    Indianapolis-based Lilly said Thursday that the Federal Trade Commission has decided that the pending licensing agreement with Sepracor can proceed.
    Lilly paid $90 million plus sales royalties to the Marlborough, Mass.-based company in 1998 for the right to sell a new version of the drug. The new medication, which still is undergoing clinical trials and is not expected to be introduced until 2002, is believed to have fewer side effects.
    A generic drug maker, New York-based Barr Laboratories, has challenged the arrangement, contending that the deal marks an attempt by Lilly to undercut competition by cheaper generic versions of the drug. But Lilly counters that the new version is significantly different than the existing Prozac compound.
    Lilly shares gained 4 to 69-1/8 in New York Stock Exchange composite trading. Merrill Lynch pharmaceutical analyst Steven Tighe upgraded the stock to "buy" from "long-term accumulate," saying that concern over the licensing pact "has been suppressing investor appetite for this stock."
    Sepracor shares jumped 16-1/4 to 85 at 4 p.m. ET on the Nasdaq. Back to top
    -- staff and wire reports

  RELATED STORIES

Lilly sets $3B share buyback - March 23, 2000

Lilly bipolar drug approved - March 17, 2000

  RELATED SITES

Eli Lilly and Co.


Note: Pages will open in a new browser window
External sites are not endorsed by CNNmoney




graphic


Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer. Morningstar: © 2018 Morningstar, Inc. All Rights Reserved. Factset: FactSet Research Systems Inc. 2018. All rights reserved. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2018 and/or its affiliates.

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer. Morningstar: © 2018 Morningstar, Inc. All Rights Reserved. Factset: FactSet Research Systems Inc. 2018. All rights reserved. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2018 and/or its affiliates.